Impact of Rapid Detection of MRSA

Mayo Clinic

Status: Withdrawn

Conditions: Staphylococcus Aureus Infections

Study type: Observational

Funder types: Other

Identifiers

NCT02027389

13-008045

Details and patient eligibility

About

The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures (both control and intervention periods)
2. Above, with rapid PBP2a testing (intervention period only).

Exclusion criteria

1. Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms in the culture).
2. Patients who have not provided MN authorization to use their medical records for research.
3. Patients who have had the FilmArray Blood culture identification diagnostic test performed on an index S. aureus blood culture.
4. Patients who have had a sterile source S. aureus culture within the prior 30 days.

Trial design

0 participants in 2 patient groups

control

Description:

Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.

intervention

Description:

Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.